BillionToOne Scores $48.5 Million

<p><strong><span class&equals;"legendSpanClass"><span class&equals;"xn-location">MENLO PARK<&sol;span><&sol;span> <&sol;strong>&&num;8212&semi; <u>BillionToOne<&sol;u>&comma; Inc&period;&comma; a molecular diagnostics company&comma; has secured an additional <span class&equals;"xn-money">&dollar;48&period;5 million<&sol;span> of funding from existing equity investors as well as upsized its Term Loan Facility with access to up to <span class&equals;"xn-money">&dollar;35 million<&sol;span>&comma; with its existing lender&comma; Bridge Bank&period; With this additional funding&comma; the Company has raised over <span class&equals;"xn-money">&dollar;280 million<&sol;span> since its first commercial product launch just three years ago&period;<&sol;p>&NewLine;<p>The <span class&equals;"xn-money">&dollar;48&period;5 million<&sol;span> funding consists of additional investments from Series C investors including Libertus Capital&comma; Hummingbird Ventures&comma; Baillie Gifford&comma; Adams Street Partners&comma; Neotribe Ventures&comma; Fifty Years VC&comma; Norwest Venture Partners&comma; and Time BioVentures&period;<&sol;p>&NewLine;<p>Since closing its <span class&equals;"xn-money">&dollar;125 million<&sol;span> Series C fundraising in <span class&equals;"xn-chron">March 2022<&sol;span>&comma; BillionToOne says it has more than doubled its test volume and revenues&period; This additional funding&comma; consisting of dilutive and non-dilutive capital&comma; strengthens the Company&&num;8217&semi;s liquidity position&comma; increases its runway to the end of 2024&comma; and provides it with the capital to execute on its growth strategy for both Prenatal and Oncology products&period; These funds will be used to continue to scale <u>UNITY Screen<&sol;u>&comma; the only commercially available non-invasive prenatal test &lpar;NIPT&rpar; that assesses fetal risk for recessive conditions and red blood cell antigen incompatibility&comma; in addition to aneuploidies&comma; and support the Company&&num;8217&semi;s plan to commercialize its liquid biopsy product line&comma; Northstar Select and Northstar Response&comma; in early 2023&period;<&sol;p>&NewLine;<p>&&num;8220&semi;I am thrilled that our existing investors and Bridge Bank are aligned with our powerful vision to transform healthcare and believe we have the right technology and team to do it&period; This additional funding speaks to their continued belief in us&period; I am honored to have each of them as our partners on this journey&comma;&&num;8221&semi; said <span class&equals;"xn-person">Oguzhan Atay<&sol;span>&comma; Ph&period;D&period;&comma; co-founder and CEO&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We have partnered with BillionToOne since its early days and have witnessed the company&&num;8217&semi;s tremendous growth&period; They have a distinguished technology platform that has been gaining momentum as is evident from the rapid scaling of its test volumes&period; We are excited to support their growth trajectory&comma; as they build a category defining company across both prenatal and oncology&comma;&&num;8221&semi; said <span class&equals;"xn-person">Firat Ileri<&sol;span> from Hummingbird Ventures&comma; a Board Member and one of the lead investors at BillionToOne&period;<&sol;p>&NewLine;<p><span class&equals;"xn-person">Brian Kirkpatrick<&sol;span>&comma; Vice President in Bridge Bank&&num;8217&semi;s Life Sciences Group stated&comma; &&num;8220&semi;BillionToOne is truly differentiated in terms of its technology and talent&period; We have witnessed their perseverance as they continue to scale at a rapid pace&period; BillionToOne has a unique mix of technology and grit that is needed to maintain their accelerated pace of growth during these evolving financial times&period;&&num;8221&semi;<&sol;p>&NewLine;<p>BillionToOne was co-founded by <span class&equals;"xn-person">Oguzhan Atay<&sol;span>&comma; Ph&period;D&period;&comma; and <span class&equals;"xn-person">David Tsao<&sol;span>&comma; Ph&period;D&period;<&sol;p>&NewLine;